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Radiation therapy aims to deliver a high therapeutic dose of ionising radiation to the 
tumour, whilst sparing surrounding healthy tissue. However, in practice, the therapeutic 
window for the applied radiation dose is often too narrow to kill the tumour efficiently. Due 
to the high atomic number and electron density of gold, gold nanoparticles (AuNPs) are an 
excellent absorber of X-rays and can be utilized to enhance the radiobiological damage to the 
tumour without increasing the radiation dose delivered externally. It has been shown that 
AuNPs are preferentially deposited at the tumour site due to an enhanced permeation and 
retention effect
1
 and can thus produce a localised dose enhancement during irradiation
2
. By 
controlling the size and surface coating, they can be further optimized for maximal uptake, 
minimal cytotoxicity and targeted deposition. The combination of radiotherapy with AuNP 
treatment increases the local radiation dose through higher absorption in the tumour site, 
which yields enhanced radiobiogical damage to cancer cells.  
Based on the hypothesis that uptake of AuNPs would increase sensitisation of cancer 
cells towards irradiation, we investigated the sensitivity and survival of LNCaP human 
prostate cancer cells after combined treatment with clinical linear accelerator, using 6 MeV 
photons in the presence of AuNPs. 
As gold is inert and not metabolized by the cell, AuNPs generally do not evoke global 
cytotoxic effects; any such effects are largely determined by the stabilizing organic coating, 
conjugated chemical groups or biomolecules attached to the surface
3-4
 as well as the particle 
size. In this study, monodisperse AuNPs were synthesized by reduction of gold salt (HAuCl4) 
with ascorbic acid as a reducing agent, which also acts as a coating agent to stabilize the 
particles in solution and controls the size distribution. The surface was further modified by 
displacing the ascorbic acid by polyethylene glycol (PEG, MW 2000) to increase 
biocompatibility and stability of the AuNPs. 
 
 
 
Figure 1: Light microscopy image (left) of LNCaP cells 24 h after treatment with AuNPs (bar indicates 20µm). 
Transmission Electron Microscopy (TEM) image (right) of clusters of AuNPs in membrane bound vesicles (bar 
indicates 500nm). 
In this study, AuNPs were designed to be 50 ± 5 nm, as this has been shown to be the 
optimal size to achieve maximal uptake in mammalian cells
5-7
while avoiding cytotoxic side 
effects seen with smaller particles. The uptake and intra-cellular distribution of the AuNPs 
were confirmed by light and transmission electron microscopy (TEM) respectively. TEM 
demonstrated that AuNP accumulate in clusters within membrane bound vesicles and 
lysosomes (Figure 1). We assessed the effects of our AuNPs alone and found no pronounced 
cytotoxicity, whereas irradiation alone reduced the level of cell metabolism by approximately 
50% (Figure 2). After the combined treatment with AuNPs and irradiation, however, the 
LNCaP cells exhibited an even higher reduction in cell viability than either treatment alone, 
as seen in Figure 2.  
 
 
These preliminary data indicate the hypothesized radio-sensitization of cancer cells in 
the presence of AuNPs, but need to be verified in further experiments. Clonogenic survival 
assays will be performed to determine the long term effects on cell viability and survival. 
Preliminary clonogenic survival results (data not shown) demonstrated a dose enhancement 
factor of approximately two times. The fraction of surviving cells after treatment with AuNPs 
only, radiation only and the combined treatment will be evaluated to calculate the 
enhancement factor introduced by the presence of AuNPs.  Subsequently, we will compare 
this dose enhancement factor obtained with the 6 MeV clinical radiotherapy beam to low 
energy superficial therapy X-rays. 
Further work will investigate the mechanism of cell killing, by assessing induction of 
double strand breaks, cell cycle profiles and apoptosis as well as the endocytotic pathway 
employed by the cell to take up the AuNPs. This result could provide valuable insights for the 
improvment of a targeted delivery to the tumour site. 
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Figure 2: Cell viability calculated as the percentage of metabolic activity using Alamar Blue according to the 
manufacturer’s protocol. The error bars represent the standard deviation of the mean of six replicates. Cell 
viability was assessed after 48 h of growth of LNCaP cells in the absence of AuNP or irradiation- treatment 
compared with cells treated with AuNP or irradiation alone and the combination of both. All gold treated cells 
were pre-incubated with AuNPs for 24 h prior to irradiation. 
